BiVictriX Therapeutics PLC
LSE:BVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BiVictriX Therapeutics PLC
Cash & Cash Equivalents
BiVictriX Therapeutics PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BiVictriX Therapeutics PLC
LSE:BVX
|
Cash & Cash Equivalents
£3.3m
|
CAGR 3-Years
56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash & Cash Equivalents
£467.7m
|
CAGR 3-Years
12%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Cash & Cash Equivalents
$149.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash & Cash Equivalents
£43.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
5%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Cash & Cash Equivalents
£96.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
|
Niox Group PLC
LSE:NIOX
|
Cash & Cash Equivalents
£19.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-19%
|
|
BiVictriX Therapeutics PLC
Glance View
BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.
See Also
What is BiVictriX Therapeutics PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
3.3m
GBP
Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Cash & Cash Equivalents amounts to 3.3m GBP.
What is BiVictriX Therapeutics PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
56%
Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for BiVictriX Therapeutics PLC have been 56% over the past three years .
